Nelson Obus, Wynnefield Capital Are Bullish on GlyEco Inc (GLYE)

Nelson Obus‘ Wynnefield Capital has solidified its position in GlyEco Inc (OTCMKTS:GLYE). According to a new filing with the SEC, Mr. Obus currently holds an aggregate of over 4.48 million shares of the company, which are equal to 8.9% of the outstanding stock. In its latest 13F, Wynnefield disclosed holding 2.25 million shares of GlyEco.

Nelson Obus

GlyEco Inc (OTCMKTS:GLYE) is a $53 million green chemistry company, whose stock declined by almost 11% since the beginning of the year. Last week, the company announced that it has finished the acquisition of MMT Technology, a glycol processing center, following several upgrades that have increased the total capacity of the facility. For the last three months of 2013, the company reported a net loss of $0.02 per share, unchanged over the quarter, with the revenue declining to around $300,000, from $370,000.

Wynnefield Capital is the only hedge fund from our database that owns shares of GlyEco Inc (OTCMKTS:GLYE). Ralph Amato, a major shareholder with around 8.0 million shares held in 2012, has been cutting its stake over the past couple of months, and during March sold around 185,000 shares, currently holding 7.59 million shares.

Wynnefield Capital holds a diversified equity portfolio, with a total value of $223.32 million. Nature’s Sunshine Prod. (NASDAQ:NATR) represents the largest holding, in which Mr. Obus holds around 1.61 million shares, with a reported value of $28.67 million. It is followed by a $19.69 million stake in Breeze-Eastern Corp (NYSEMKT:BZC) and $19.14 million in Landec Corporation (NASDAQ:LNDC), the positions amassing 2.12 million shares and 1.64 million shares respectively.

Disclosure: none

Recommended Reading:

David Einhorn, Greenlight Capital Raise Stake in BioFuel Energy Corp. (BIOF); Send Business Proposal To Board

Wexford Capital Reveals New Position in Famous Dave’s of America, Inc.(DAVE)

Leon Cooperman is Bullish on London-listed Monitise Plc (MONI) and Raises Stake to 10.9%

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!